TriSalus Life Sciences (TLSI) Stock Forecast & Price Target

Compare

67 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TLSI Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

TriSalus

Life Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TLSI Stock 12 Month Forecast

Average Price Target

$11.60

▲(58.90% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for TriSalus Life Sciences in the last 3 months. The average price target is $11.60 with a high forecast of $16.00 and a low forecast of $10.00. The average price target represents a 58.90% change from the last price of $7.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","10":"$10","17":"$17","6.5":"$6.5","13.5":"$13.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,6.5,10,13.5,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.74,5.6061538461538465,6.472307692307693,7.338461538461539,8.204615384615385,9.07076923076923,9.936923076923076,10.803076923076922,11.669230769230769,12.535384615384615,13.401538461538461,14.267692307692307,15.133846153846154,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.74,5.2676923076923075,5.795384615384616,6.323076923076924,6.850769230769231,7.378461538461538,7.906153846153846,8.433846153846154,8.961538461538462,9.489230769230769,10.016923076923078,10.544615384615385,11.072307692307692,{"y":11.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.74,5.144615384615385,5.549230769230769,5.953846153846154,6.358461538461539,6.763076923076923,7.167692307692308,7.572307692307692,7.976923076923077,8.381538461538462,8.786153846153846,9.19076923076923,9.595384615384615,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.01,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.24,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.01,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.11,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.76,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.21,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.18,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.16,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.56,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.74,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$16.00

Average Price Target$11.60

Lowest Price Target$10.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

William Plovanic

Canaccord Genuity

$11

Buy

50.68%

Upside

Reiterated

11/20/25

TriSalus Life Sciences: Strong Growth Prospects and Strategic Developments Reinforce Buy RatingBottom line: We hosted TriSalus’ CEO Mary Szela and CFO a fireside chat at our annual Health & Services Forum. We spoke about the company’s recent Q4 results, guidance, operating leverage expectations, product pipeline, and new mapping reimbursement code. While Q3 revenue missed consensus, we continue to be confident in the company’s ability to hit 50% Y/Y growth given the commentary on strong performance in August and September. We are also optimistic about TriNav’s utility across many IR use cases and believe the mapping code and portfolio of various iterations will drive deeper adoption.

Jason McCarthy

Maxim Group

$16

Buy

119.18%

Upside

Reiterated

11/17/25

TriSalus Life Sciences: Strong Revenue Growth and Strategic Initiatives Drive Buy Rating

Justin Walsh

JonesTrading

$11

Buy

50.68%

Upside

Reiterated

11/14/25

TriSalus Life Sciences: Promising Growth and Strategic Expansions Justify Buy Rating

Suraj Kalia

Oppenheimer

$10

Buy

36.99%

Upside

Reiterated

11/14/25

Oppenheimer Remains a Buy on TriSalus Life Sciences (TLSI)

Frank Takkinen

Lake Street

$10

Buy

36.99%

Upside

Reiterated

11/14/25

Lake Street Sticks to Their Buy Rating for TriSalus Life Sciences (TLSI)

Ross Osborn

Cantor Fitzgerald

Buy

23.29%

Upside

Reiterated

06/09/25

TriSalus Life Sciences (TLSI) Receives a Buy from Cantor Fitzgerald

Jason Wittes

Roth MKM

$11

Buy

50.68%

Upside

Reiterated

05/21/25

Roth MKM Reaffirms Their Buy Rating on TriSalus Life Sciences (TLSI)

Carl Byrnes

Northland Securities

$12.5

Buy

71.23%

Upside

Reiterated

04/30/25

Northland reiterates Outperform Rating on TriSalus Life Sciences, Inc. (TLSI)Northland analyst Carl Byrnes reiterated an Outperform rating and $12.50 price target on TriSalus Life Sciences, Inc. (NASDAQ: TLSI)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

William Plovanic

Canaccord Genuity

$11

Buy

50.68%

Upside

Reiterated

11/20/25

Jason McCarthy

Maxim Group

$16

Buy

119.18%

Upside

Reiterated

11/17/25

TriSalus Life Sciences: Strong Revenue Growth and Strategic Initiatives Drive Buy Rating

Justin Walsh

JonesTrading

$11

Buy

50.68%

Upside

Reiterated

11/14/25

TriSalus Life Sciences: Promising Growth and Strategic Expansions Justify Buy Rating

Suraj Kalia

Oppenheimer

$10

Buy

36.99%

Upside

Reiterated

11/14/25

Oppenheimer Remains a Buy on TriSalus Life Sciences (TLSI)

Frank Takkinen

Lake Street

$10

Buy

36.99%

Upside

Reiterated

11/14/25

Lake Street Sticks to Their Buy Rating for TriSalus Life Sciences (TLSI)

Ross Osborn

Cantor Fitzgerald

Buy

23.29%

Upside

Reiterated

06/09/25

TriSalus Life Sciences (TLSI) Receives a Buy from Cantor Fitzgerald

Jason Wittes

Roth MKM

$11

Buy

50.68%

Upside

Reiterated

05/21/25

Roth MKM Reaffirms Their Buy Rating on TriSalus Life Sciences (TLSI)

Carl Byrnes

Northland Securities

$12.5

Buy

71.23%

Upside

Reiterated

04/30/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering TriSalus Life Sciences

1 Month

xxx

Success Rate

5/7 ratings generated profit

Average Return

+15.04%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +15.04% per trade.

3 Months

xxx

Success Rate

4/9 ratings generated profit

Average Return

-1.08%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of -1.08% per trade.

1 Year

Frank TakkinenLake Street

Success Rate

7/7 ratings generated profit

Average Return

+52.30%

reiterated a buy rating last month

Copying Frank Takkinen's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +52.30% per trade.

2 Years

xxx

Success Rate

7/7 ratings generated profit

Average Return

+52.30%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +52.30% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TLSI Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TLSI has received 9 Buy Ratings, 10 Hold Ratings, and 1 Sell Ratings. TLSI average Analyst price target in the past 3 months is 11.60.

Each month's total comprises the sum of three months' worth of ratings.

TLSI Financial Forecast

TLSI Earnings Forecast

Next quarter’s earnings estimate for TLSI is -$0.12 with a range of -$0.17 to -$0.09. The previous quarter’s EPS was -$0.96. TLSI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year TLSI has Performed in-line its overall industry.

TLSI Sales Forecast

Next quarter’s sales forecast for TLSI is $12.81M with a range of $12.10M to $13.40M. The previous quarter’s sales results were $11.57M. TLSI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year TLSI has Performed in-line its overall industry.

TLSI Stock Forecast FAQ

What is TLSI’s average 12-month price target, according to analysts?

Based on analyst ratings, TriSalus Life Sciences’s 12-month average price target is 11.60.

What is TLSI’s upside potential, based on the analysts’ average price target?

TriSalus Life Sciences has 58.90% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TLSI a Buy, Sell or Hold?

TriSalus Life Sciences has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is TriSalus Life Sciences’s price target?

The average price target for TriSalus Life Sciences is 11.60. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $16.00 ,the lowest forecast is $10.00. The average price target represents 58.90% Increase from the current price of $7.3.

What do analysts say about TriSalus Life Sciences?

TriSalus Life Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of TLSI?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

TriSalus Life Sciences (TLSI) Stock Forecast & Price Target

TLSI Analyst Ratings

TLSI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering TriSalus Life Sciences

TLSI Analyst Recommendation Trends

TLSI Financial Forecast

TLSI Earnings Forecast

TLSI Sales Forecast

TLSI Stock Forecast FAQ

Detailed List of Analyst Forecasts